Bio-Techne Faces NIH & Tariff Uncertainty–Can They Outpace Policy Risks?

Bio-Techne Corporation recently shared their financial outcomes for the fourth quarter and the fiscal year 2025. The company reported a solid quarter, with a 3% organic revenue growth driven mainly by the biopharma end markets, particularly among large pharmaceutical clients. This growth was attributed to the company’s products, such as automated proteomic analytical instruments and cell therapy solutions. For the fiscal year, Bio-Techne achieved a 5% organic revenue growth, launching several products that reinforced their market leadership.